Bausch + Lomb Publishes Phase 4 Data on the Early Effects of Miebo for Dry Eye Disease

Bausch + Lomb Publishes Phase 4 Data on the Early Effects of Miebo for Dry Eye Disease

Bausch + Lomb announced that Ophthalmology and Therapy has published results from a phase 4 study which assessed early patient-reported outcomes with Miebo in patients with dry eye disease (DED). Miebo, indicated for the signs and symptoms of DED, is the first and only prescription treatment to directly target tear evaporation, according to B+L. The study examined the results of Miebo after the first use and during the first 2 weeks of treatment…